FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2945553324> ?p ?o ?g. }

• W2945553324 endingPage "811" @default.
• W2945553324 startingPage "804" @default.
• W2945553324 abstract "Objective To evaluate the clinical impact of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography on the planned management of prostate cancer patients with biochemical recurrence after surgery. Methods We enrolled 276 prostate cancer patients referred to 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography due to biochemical recurrence after surgery (two consecutive prostate-specific antigen assays ≥0.2 ng/mL). First, the detection rate of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed according to different prostate-specific antigen levels. Second, the independent predictors of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography positive results were assessed. Finally, the intended treatment before revision of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was assessed by a multidisciplinary team based on the European Association of Urology guidelines, patient clinical condition and clinical parameters. Then, re-assessment of the treatment plan was prospectively recorded by the same board after revision of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography. The effective clinical impact of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was rated as major (change in therapeutic approach), minor (same treatment, but modified therapeutic strategy) or none. Results The overall detection rate of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 47.5%. Prostate-specific antigen at 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (odds ratio 3.52) and prostate-specific antigen doubling time <3 months (odds ratio 3.98) were independent predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography results (all P ≤ 0.03). 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography led to a major treatment change in 177 cases (64.1%), with a minor clinical impact of 2.5%. The overall clinical impact of 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography was 42.4%, 27.7%, 21.2% and 8.7% in men with prostate-specific antigen at 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography of 0.2–0.4, 0.5–1, 1.1–2 and >2 ng/mL, respectively. Conclusions 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography allows clinicians to radically change the intended treatment approach before imaging evaluation, in roughly two out three individuals." @default.
• W2945553324 created "2019-05-29" @default.
• W2945553324 creator A5001615562 @default.
• W2945553324 creator A5006892381 @default.
• W2945553324 creator A5009887316 @default.
• W2945553324 creator A5017414279 @default.
• W2945553324 creator A5019549204 @default.
• W2945553324 creator A5029088271 @default.
• W2945553324 creator A5032229878 @default.
• W2945553324 creator A5040296208 @default.
• W2945553324 creator A5060396380 @default.
• W2945553324 creator A5071800483 @default.
• W2945553324 creator A5080019020 @default.
• W2945553324 creator A5080774729 @default.
• W2945553324 creator A5083426889 @default.
• W2945553324 creator A5084290670 @default.
• W2945553324 creator A5090801942 @default.
• W2945553324 date "2019-05-13" @default.
• W2945553324 modified "2023-10-16" @default.
• W2945553324 title "How does ⁶⁸ Ga‐prostate‐specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?" @default.
• W2945553324 cites W1900676315 @default.
• W2945553324 cites W2007912355 @default.
• W2945553324 cites W2014999922 @default.
• W2945553324 cites W2038068686 @default.
• W2945553324 cites W2043601120 @default.
• W2945553324 cites W2069380387 @default.
• W2945553324 cites W2211198407 @default.
• W2945553324 cites W2326657743 @default.
• W2945553324 cites W2393681916 @default.
• W2945553324 cites W2412413888 @default.
• W2945553324 cites W2416073795 @default.
• W2945553324 cites W2470255787 @default.
• W2945553324 cites W2511949746 @default.
• W2945553324 cites W2547875381 @default.
• W2945553324 cites W2615655377 @default.
• W2945553324 cites W2617065467 @default.
• W2945553324 cites W2736737591 @default.
• W2945553324 cites W2766371188 @default.
• W2945553324 cites W2774325924 @default.
• W2945553324 cites W2775321189 @default.
• W2945553324 cites W2785084154 @default.
• W2945553324 cites W2794422949 @default.
• W2945553324 cites W2801398567 @default.
• W2945553324 cites W2808437932 @default.
• W2945553324 cites W2808736367 @default.
• W2945553324 cites W286096609 @default.
• W2945553324 doi "https://doi.org/10.1111/iju.14012" @default.
• W2945553324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31083784" @default.
• W2945553324 hasPublicationYear "2019" @default.
• W2945553324 type Work @default.
• W2945553324 sameAs 2945553324 @default.
• W2945553324 citedByCount "19" @default.
• W2945553324 countsByYear W29455533242019 @default.
• W2945553324 countsByYear W29455533242020 @default.
• W2945553324 countsByYear W29455533242021 @default.
• W2945553324 countsByYear W29455533242022 @default.
• W2945553324 countsByYear W29455533242023 @default.
• W2945553324 crossrefType "journal-article" @default.
• W2945553324 hasAuthorship W2945553324A5001615562 @default.
• W2945553324 hasAuthorship W2945553324A5006892381 @default.
• W2945553324 hasAuthorship W2945553324A5009887316 @default.
• W2945553324 hasAuthorship W2945553324A5017414279 @default.
• W2945553324 hasAuthorship W2945553324A5019549204 @default.
• W2945553324 hasAuthorship W2945553324A5029088271 @default.
• W2945553324 hasAuthorship W2945553324A5032229878 @default.
• W2945553324 hasAuthorship W2945553324A5040296208 @default.
• W2945553324 hasAuthorship W2945553324A5060396380 @default.
• W2945553324 hasAuthorship W2945553324A5071800483 @default.
• W2945553324 hasAuthorship W2945553324A5080019020 @default.
• W2945553324 hasAuthorship W2945553324A5080774729 @default.
• W2945553324 hasAuthorship W2945553324A5083426889 @default.
• W2945553324 hasAuthorship W2945553324A5084290670 @default.
• W2945553324 hasAuthorship W2945553324A5090801942 @default.
• W2945553324 hasBestOaLocation W29455533241 @default.
• W2945553324 hasConcept C121608353 @default.
• W2945553324 hasConcept C126322002 @default.
• W2945553324 hasConcept C126838900 @default.
• W2945553324 hasConcept C163716698 @default.
• W2945553324 hasConcept C20417620 @default.
• W2945553324 hasConcept C2775842073 @default.
• W2945553324 hasConcept C2776235491 @default.
• W2945553324 hasConcept C2777008409 @default.
• W2945553324 hasConcept C2779466945 @default.
• W2945553324 hasConcept C2780192828 @default.
• W2945553324 hasConcept C2781406297 @default.
• W2945553324 hasConcept C2908761598 @default.
• W2945553324 hasConcept C2989005 @default.
• W2945553324 hasConcept C37097830 @default.
• W2945553324 hasConcept C71924100 @default.
• W2945553324 hasConceptScore W2945553324C121608353 @default.
• W2945553324 hasConceptScore W2945553324C126322002 @default.
• W2945553324 hasConceptScore W2945553324C126838900 @default.
• W2945553324 hasConceptScore W2945553324C163716698 @default.
• W2945553324 hasConceptScore W2945553324C20417620 @default.
• W2945553324 hasConceptScore W2945553324C2775842073 @default.
• W2945553324 hasConceptScore W2945553324C2776235491 @default.
• W2945553324 hasConceptScore W2945553324C2777008409 @default.
• W2945553324 hasConceptScore W2945553324C2779466945 @default.

• next